Ovarian Hyperstimulation Syndrome after GnRH Agonist Triggering and Freeze-All Protocol? Never Not, Hardly Ever: A Systematic Review of Case Reports

Introduction: Ovarian hyperstimulation syndrome (OHSS) is a severe complication associated with controlled ovarian stimulation (COS). GnRH agonist (GnRH-a) triggering is considered an efficient strategy to prevent OHSS in the high-risk patient. Methods: We performed a review of 11 cases of early and severe OHSS following GnRH-a triggering and freeze-all protocol. Electronic databases were searched from inception of each database until October 2021, to identify case reports and case series that reported OHSS after GnRH-a triggering and freeze-all approach describing patient demographics, COS protocol, and patient outcomes. Results: From the literature review, it is possible to suggest that (1) following GnRH-a triggering, the risk of early and severe OHSS is not totally cancelled; (2) despite it is not possible to predict the event, polycystic ovary syndrome is the most common risk factor; (3) the use of GnRH antagonist starting from the day of PU may represent a valid strategy for preventing OHSS in women with high-risk profile; (4) following the unexpected onset of OHSS, measuring serum levels of human chorionic gonadotropin (hCG) is helpful to exclude an inadvertent exogenous administration or a pregnancy. Conclusion: The statement that OHSS risk is eliminated when GnRH-a triggering, a freeze-all strategy, and no hCG in the luteal phase may generate the idea that this event cannot occur. Although rare, these cases have been observed in a relatively short period of time.

[1]  R. Vallone,et al.  Severe Ovarian Hyperstimulation Syndrome in a Woman With Breast Cancer Under Letrozole Triggered With GnRH Agonist: A Case Report and Review of the Literature , 2021, Frontiers in Reproductive Health.

[2]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[3]  C. Herndon,et al.  Severe ovarian hyperstimulation syndrome associated with long-acting GnRH agonist in oncofertility patients , 2021, Journal of Assisted Reproduction and Genetics.

[4]  A. Andrisani,et al.  Which is the optimal timing for starting chemoprotection with gonadotropin-releasing hormone agonists after oocyte cryopreservation? Reflections on a critical case of ovarian hyperstimulation syndrome. , 2020, Journal of gynecology obstetrics and human reproduction.

[5]  M. Saini,et al.  Severe early-onset ovarian hyperstimulation syndrome with liver dysfunction in an IVF segmentation cycle , 2020, BMJ Case Reports.

[6]  D. Cimadomo,et al.  Pharmacogenetics of FSH Action in the Female , 2019, Front. Endocrinol..

[7]  S. Seneca,et al.  Rare genetic variants potentially involved in ovarian hyperstimulation syndrome , 2018, Journal of Assisted Reproduction and Genetics.

[8]  A. S. Laganà,et al.  Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve , 2018, Archives of Gynecology and Obstetrics.

[9]  S. Esteves,et al.  Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis , 2018, Human reproduction update.

[10]  R. Orvieto,et al.  Ovarian hyperstimulation syndrome following GnRH agonist trigger—think ectopic , 2017, Journal of Assisted Reproduction and Genetics.

[11]  M. Pisarska,et al.  Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. , 2016, Fertility and sterility.

[12]  J. Bogstad,et al.  Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles. , 2016, Human reproduction.

[13]  Shilpa Sharma,et al.  Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis , 2015, Journal of human reproductive sciences.

[14]  S. Seneca,et al.  Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition , 2015, Journal of Assisted Reproduction and Genetics.

[15]  A. Arıcı,et al.  The Emerging Role of Angiogenic Factor Dysregulation in the Pathogenesis of Polycystic Ovarian Syndrome , 2015, Seminars in Reproductive Medicine.

[16]  F. Gode,et al.  Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. , 2014, Reproductive biomedicine online.

[17]  J. Chan,et al.  GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at 'freeze-all strategy'. , 2014, Reproductive biomedicine online.

[18]  P. Devroey,et al.  Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. , 2014, Fertility and sterility.

[19]  S. Sunkara,et al.  Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. , 2014, Human reproduction update.

[20]  P. Humaidan,et al.  GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.

[21]  E. Kolibianakis,et al.  Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study , 2012, Reproductive Biology and Endocrinology.

[22]  M. Fritz,et al.  Severe ovarian hyperstimulation syndrome after letrozole-gonadotropin stimulation: a case report , 2012, Journal of Assisted Reproduction and Genetics.

[23]  G. Griesinger,et al.  Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study. , 2011, Fertility and sterility.

[24]  M. van Wely,et al.  GnRHa to trigger final oocyte maturation: a time to reconsider. , 2010, Human reproduction.

[25]  H. Kliem,et al.  Effect of the luteinising hormone surge on regulation of vascular endothelial growth factor and extracellular matrix-degrading proteinases and their inhibitors in bovine follicles. , 2008, Reproduction, fertility, and development.

[26]  E. Metzen,et al.  Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. , 2006, Fertility and sterility.

[27]  P. Humaidan,et al.  Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. , 2006, Reproductive biomedicine online.

[28]  H. Tournaye,et al.  Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. , 2006, Fertility and sterility.

[29]  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. , 2004, Fertility and sterility.

[30]  K. Osteen,et al.  The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. , 2003, Endocrine reviews.

[31]  B. Berisha,et al.  Stimulatory and synergistic effects of luteinising hormone and insulin like growth factor 1 on the secretion of vascular endothelial growth factor and progesterone of cultured bovine granulosa cells. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[32]  R. Jaffe,et al.  Role of vascular endothelial growth factor in ovarian physiology and pathology. , 2000, Fertility and sterility.

[33]  M. Breckwoldt,et al.  Human chorionic gonadotropin-dependent expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. , 1995, The Journal of clinical endocrinology and metabolism.

[34]  L. Kahana,et al.  Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. , 1991, Fertility and sterility.

[35]  W. Shen,et al.  Disappearance of exogenously administered human chorionic gonadotropin. , 1989, Fertility and sterility.

[36]  B. Little,et al.  Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. , 1968, The Journal of clinical endocrinology and metabolism.